Literature DB >> 19275719

MenA is a promising drug target for developing novel lead molecules to combat Mycobacterium tuberculosis.

Michio Kurosu1, Dean C Crick.   

Abstract

Potent inhibitors of MenA (1,4-dihydroxy-2-naphtoate prenyltrasferase) in Mycobacterium tuberculosis are identified, and are also effective in inhibiting growth of Mycobacterium tuberculosis at low concentrations. The MenA inhibitors possess common chemical structural features of (alkylamino)oalkoxyphenyl)(phenyl)methanones. Significantly, the MenA inhibitors can be synthesized in a few steps with high overall yields. The representative MenA inhibitors are highly effective in killing nonreplicating Mycobacterium tuberculosis that is evaluated by using the Wayne low oxygen model. In addition, a series of drug resistant Mycobacterium spp. are sensitive to the MenA inhibitors. The results are expected to be of significance in terms of discovering new lead compounds that can be developed into new drugs to combat unmet diseases caused by Mycobacterium tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19275719      PMCID: PMC5378063          DOI: 10.2174/157340609787582882

Source DB:  PubMed          Journal:  Med Chem        ISSN: 1573-4064            Impact factor:   2.745


  29 in total

1.  Proteins of Mycobacterium bovis BCG induced in the Wayne dormancy model.

Authors:  C Boon; R Li; R Qi; T Dick
Journal:  J Bacteriol       Date:  2001-04       Impact factor: 3.490

Review 2.  Prospects for new antitubercular drugs.

Authors:  Ken Duncan; Clifton E Barry
Journal:  Curr Opin Microbiol       Date:  2004-10       Impact factor: 7.934

3.  SOSUI: classification and secondary structure prediction system for membrane proteins.

Authors:  T Hirokawa; S Boon-Chieng; S Mitaku
Journal:  Bioinformatics       Date:  1998       Impact factor: 6.937

4.  An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence.

Authors:  L G Wayne; L G Hayes
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

5.  Menaquinone (vitamin K2) biosynthesis: localization and characterization of the menA gene from Escherichia coli.

Authors:  K Suvarna; D Stevenson; R Meganathan; M E Hudspeth
Journal:  J Bacteriol       Date:  1998-05       Impact factor: 3.490

6.  Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase.

Authors:  J D McKinney; K Höner zu Bentrup; E J Muñoz-Elías; A Miczak; B Chen; W T Chan; D Swenson; J C Sacchettini; W R Jacobs; D G Russell
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

7.  Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis.

Authors:  L G Wayne; H A Sramek
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

8.  Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Analysis of early (6-month) mortality.

Authors:  P Nunn; R Brindle; L Carpenter; J Odhiambo; K Wasunna; R Newnham; W Githui; S Gathua; M Omwega; K McAdam
Journal:  Am Rev Respir Dis       Date:  1992-10

9.  Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo.

Authors:  Anne J Lenaerts; Casey Bitting; Lisa Woolhiser; Veronica Gruppo; Karen S Marietta; Christine M Johnson; Ian M Orme
Journal:  Antimicrob Agents Chemother       Date:  2008-02-11       Impact factor: 5.191

10.  Utility of interferon-gamma ELISPOT assay responses in highly tuberculosis-exposed patients with advanced HIV infection in South Africa.

Authors:  Stephen D Lawn; Nonzwakazi Bangani; Monica Vogt; Linda-Gail Bekker; Motasim Badri; Marjorie Ntobongwana; Hazel M Dockrell; Robert J Wilkinson; Robin Wood
Journal:  BMC Infect Dis       Date:  2007-08-28       Impact factor: 3.090

View more
  23 in total

1.  Identification of point mutations in clinical Staphylococcus aureus strains that produce small-colony variants auxotrophic for menadione.

Authors:  Melissa A Dean; Randall J Olsen; S Wesley Long; Adriana E Rosato; James M Musser
Journal:  Infect Immun       Date:  2014-01-22       Impact factor: 3.441

Review 2.  The tuberculosis drug discovery and development pipeline and emerging drug targets.

Authors:  Khisimuzi Mdluli; Takushi Kaneko; Anna Upton
Journal:  Cold Spring Harb Perspect Med       Date:  2015-01-29       Impact factor: 6.915

3.  Discovery of selective menaquinone biosynthesis inhibitors against Mycobacterium tuberculosis.

Authors:  Joy Debnath; Shajila Siricilla; Bajoie Wan; Dean C Crick; Anne J Lenaerts; Scott G Franzblau; Michio Kurosu
Journal:  J Med Chem       Date:  2012-04-06       Impact factor: 7.446

4.  Methods for Structural and Functional Analyses of Intramembrane Prenyltransferases in the UbiA Superfamily.

Authors:  Y Yang; N Ke; S Liu; W Li
Journal:  Methods Enzymol       Date:  2016-12-07       Impact factor: 1.600

5.  Allosteric regulation of menaquinone (vitamin K2) biosynthesis in the human pathogen Mycobacterium tuberculosis.

Authors:  Ghader Bashiri; Laura V Nigon; Ehab N M Jirgis; Ngoc Anh Thu Ho; Tamsyn Stanborough; Stephanie S Dawes; Edward N Baker; Esther M M Bulloch; Jodie M Johnston
Journal:  J Biol Chem       Date:  2020-02-06       Impact factor: 5.157

6.  Mechanism of MenE inhibition by acyl-adenylate analogues and discovery of novel antibacterial agents.

Authors:  Joe S Matarlo; Christopher E Evans; Indrajeet Sharma; Lubens J Lavaud; Stephen C Ngo; Roger Shek; Kanagalaghatta R Rajashankar; Jarrod B French; Derek S Tan; Peter J Tonge
Journal:  Biochemistry       Date:  2015-10-15       Impact factor: 3.162

7.  Application of Mycobacterium smegmatis as a surrogate to evaluate drug leads against Mycobacterium tuberculosis.

Authors:  Nada Lelovic; Katsuhiko Mitachi; Junshu Yang; Maddie R Lemieux; Yinduo Ji; Michio Kurosu
Journal:  J Antibiot (Tokyo)       Date:  2020-05-29       Impact factor: 2.649

8.  Accumulation of heptaprenyl diphosphate sensitizes Bacillus subtilis to bacitracin: implications for the mechanism of resistance mediated by the BceAB transporter.

Authors:  Anthony W Kingston; Heng Zhao; Gregory M Cook; John D Helmann
Journal:  Mol Microbiol       Date:  2014-05-23       Impact factor: 3.501

9.  Self-control of vitamin K2 production captured in the crystal.

Authors:  Mickaël Blaise; Laurent Kremer
Journal:  J Biol Chem       Date:  2020-03-20       Impact factor: 5.157

10.  A Methyl 4-Oxo-4-phenylbut-2-enoate with in Vivo Activity against MRSA that Inhibits MenB in the Bacterial Menaquinone Biosynthesis Pathway.

Authors:  Joe S Matarlo; Yang Lu; Fereidoon Daryaee; Taraneh Daryaee; Bela Ruzsicska; Stephen G Walker; Peter J Tonge
Journal:  ACS Infect Dis       Date:  2016-03-07       Impact factor: 5.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.